GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Total Stockholders Equity

SinoMab BioScience (HKSE:03681) Total Stockholders Equity : HK$205.97 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Total Stockholders Equity?

SinoMab BioScience's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$205.97 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SinoMab BioScience's Book Value per Share for the quarter that ended in Dec. 2024 was HK$0.19. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SinoMab BioScience's Debt-to-Equity for the quarter that ended in Dec. 2024 was 2.50.

SinoMab BioScience Total Stockholders Equity Historical Data

The historical data trend for SinoMab BioScience's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Total Stockholders Equity Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial 1,170.04 832.92 569.05 323.30 205.97

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 569.05 444.23 323.30 298.13 205.97

SinoMab BioScience  (HKSE:03681) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SinoMab BioScience's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(205.966-0)/1091.755
=0.19

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SinoMab BioScience's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(134.078 + 380.829) / 205.966
=2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SinoMab BioScience Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SinoMab BioScience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Total Stockholders Equity
Comparable Companies
HKSE:02137 HKSE:01875 HKSE:02566 HKSE:02563 HKSE:06998 HKSE:06996 HKSE:02181 HKSE:02487 HKSE:06622 HKSE:02496 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
Website
https://www.sinomab.com
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Liu Wenyi 2201 Interest of corporation controlled by you
Qiang Jing
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Leung Shui On 2201 Interest of corporation controlled by you
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines